Aware Super Pty Ltd as trustee of Aware Super Buys Shares of 61,501 West Pharmaceutical Services, Inc. $WST

Aware Super Pty Ltd as trustee of Aware Super bought a new position in West Pharmaceutical Services, Inc. (NYSE:WST) during the 1st quarter, HoldingsChannel reports. The firm bought 61,501 shares of the medical instruments supplier’s stock, valued at approximately $15,415,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in WST. Elyxium Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the 4th quarter valued at $25,000. Bayban bought a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at $27,000. Private Trust Co. NA raised its stake in West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 61 shares during the period. DV Equities LLC bought a new position in West Pharmaceutical Services during the fourth quarter worth about $28,000. Finally, International Assets Investment Management LLC bought a new position in West Pharmaceutical Services during the fourth quarter worth about $31,000. 93.90% of the stock is owned by institutional investors.

Insider Buying and Selling at West Pharmaceutical Services

In other news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Stock Up 0.9%

WST stock opened at $362.08 on Friday. The company has a market cap of $25.58 billion, a price-to-earnings ratio of 48.41, a P/E/G ratio of 2.91 and a beta of 1.16. West Pharmaceutical Services, Inc. has a twelve month low of $206.80 and a twelve month high of $367.66. The business has a 50 day moving average price of $332.06 and a two-hundred day moving average price of $284.28. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on WST. Evercore restated an “outperform” rating and issued a $410.00 price target on shares of West Pharmaceutical Services in a report on Monday, July 6th. Stephens reiterated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Morgan Stanley increased their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Finally, Wolfe Research started coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Buy” and a consensus price target of $363.17.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.